Human induced pluripotent stem cell-derived versus adult cardiomyocytes: An in silico electrophysiological study on effects of ionic current block

British Journal of Pharmacology

Volumn 172, Issue 21, 2015, Pages 5147-5160

  Paci, M ^a   Hyttinen, J ^a   Rodriguez, B ^b   Severi, S ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; INWARDLY RECTIFYING POTASSIUM CHANNEL; SODIUM CALCIUM EXCHANGE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT;

ARTICLE; CONTROLLED STUDY; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; ION CURRENT; PHARMACOLOGICAL BLOCKING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; SENSITIVITY ANALYSIS; ACTION POTENTIAL; ADULT; CARDIAC MUSCLE CELL; COMPUTER SIMULATION; CYTOLOGY; DRUG EFFECTS; INDUCED PLURIPOTENT STEM CELL; PHYSIOLOGY;

ACTION POTENTIALS; ADULT; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; COMPUTER SIMULATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC;

EID: 84945893883     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13282     Document Type: Article

References (57)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013b). The Concise Guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol 170: 1706-1796.
3. Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, et al., (2013). Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J 32: 3161-3175.
4. Brennan T, Fink M, Rodriguez B, (2009). Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. Eur J Pharm Sci 36: 62-77.
5. Britton OJ, Bueno-Orovio A, Van Ammel K, Lu HR, Towart R, Gallacher DJ, et al., (2013). Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology. Proc Natl Acad Sci U S A 110: E2098-E2105.
6. Carmeliet E, (2006). Repolarization reserve in cardiac cells. J Med Biol Eng 26: 97-105.
7. Carusi A, Burrage K, Rodríguez B, (2012). Bridging experiments, models and simulations: an integrative approach to validation in computational cardiac electrophysiology. Am J Physiol Heart Circ Physiol 303: H144-H155.
8. Christophe B, (2013). Simulation of early after-depolarisation in non-failing human ventricular myocytes: can this help cardiac safety pharmacology? Pharmacol Rep 65: 1281-1293.
9. Davies MR, Mistry HB, Hussein L, Pollard CE, Valentin J-P, Swinton J, et al., (2012). An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. AJP-Heart Circ Physiol 302: H1466-H1480.
10. Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, et al., (2012). Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res 95: 419-429.
11. Fu J-D, Jiang P, Rushing S, Liu J, Chiamvimonvat N, Li RA, (2010). Na+/Ca2+ exchanger is a determinant of excitation-contraction coupling in human embryonic stem cell-derived ventricular cardiomyocytes. Stem Cells Dev 19: 773-782.
12. Gemmell P, Burrage K, Rodriguez B, Quinn TA, (2014). Population of computational rabbit-specific ventricular action potential models for investigating sources of variability in cellular repolarisation. PLoS One 9: e90112.
13. de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S, et al., (2006). AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation 114: 1234-1242.
14. Hamdam J, Sethu S, Smith T, Alfirevic A, Alhaidari M, Atkinson J, et al., (2013). Safety pharmacology-current and emerging concepts. Toxicol Appl Pharmacol 273: 229-241.
15. Heist EK, Ruskin JN, (2010). Drug-induced arrhythmia. Circulation 122: 1426-1435.
16. Hoekstra M, Mummery CL, Wilde A a M, Bezzina CR, Verkerk AO, (2012). Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol 3: 346.
17. Itoh H, Naito Y, Tomita M, (2007). Simulation of developmental changes in action potentials with ventricular cell models. Syst Synth Biol 1: 11-23.
18. Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, et al., (2012). Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol 60: 990-1000.
19. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al., (2011). Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471: 225-229.
20. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, et al., (2012). Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 4: 180-191.
21. Kannankeril P, (2010). Drug-induced long QT syndrome. Pharmacol Rev 62: 760-781.
22. Knollmann BC, (2013). Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model? Circ Res 112: 969-976.
23. Kormos A, Nagy N, Acsai K, Váczi K, Ágoston S, Pollesello P, et al., (2014). Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion. Eur J Pharmacol 740: 539-551.
24. Kujala K, Paavola J, Lahti A, Larsson K, Pekkanen-Mattila M, Viitasalo M, et al., (2012). Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS One 7: e44660.
25. Lahti AL, Kujala VJ, Chapman H, Koivisto A-P, Pekkanen-Mattila M, Kerkela E, et al., (2012). Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 5: 220-230.
26. Leishman DJ, Beck TW, Dybdal N, Gallacher DJ, Guth BD, Holbrook M, et al., (2012). Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society. J Pharmacol Toxicol Methods 65: 93-101.
27. Li G, Feng J, Yue L, Carrier M, (1998). Transmural heterogeneity of action potentials and Ito1 in myocytes isolated from the human right ventricle. Am J Physiol 275: H369-H377.
28. Li S, Chen G, Li RA, (2013). Calcium signaling of human pluripotent stem cell-derived cardiomyocytes. J Physiol 591: 5279-5290.
29. Liu J, Fu JD, Siu CW, Li RA, (2007). Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation. Stem Cells 25: 3038-3044.
30. Ma D, Wei H, Zhao Y, Lu J, Li G, Binte N, et al., (2013). Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int J Cardiol 168: 5277-5286.
31. Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, et al., (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. AJP-Heart Circ Physiol 301: H2006-H2017.
32. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, et al., (2011). Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32: 952-962.
33. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, et al., (2011). Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 91: 53-61.
34. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, et al., (2010). Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363: 1397-1409.
35. Nagy N, Kormos A, Kohajda Z, Szebeni Á, Szepesi J, Pollesello P, et al., (2014). Selective Na(+) /Ca(2+) exchanger inhibition prevents Ca(2+) overload-induced triggered arrhythmias. Br J Pharmacol 171: 5665-5681.
36. O'Hara T, Virág L, Varrõ A, Rudy Y, (2011). Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 7: e1002061.
37. Paci M, Hyttinen J, Aalto-Setälä K, Severi S, (2013a). Computational models of ventricular- and atrial-like human induced pluripotent stem cell derived cardiomyocytes. Ann Biomed Eng 41: 2334-2348.
38. Paci M, Hyttinen J, Severi S, (2013b). Computational modelling of LQT1 in human induced pluripotent stem cell derived cardiomyocytes. Comput Cardiol 40: 1239-1242.
39. Paci M, Sartiani L, Lungo M, Jaconi M, Mugelli A, Cerbai E, et al., (2012). Mathematical modelling of the action potential of human embryonic stem cell derived cardiomyocytes. Biomed Eng Online 11: 61.
40. Paci M, Severi S, Hyttinen J, (2014). Computational modeling supports induced pluripotent stem cell-derived cardiomyocytes reliability as a model for human LQT3. Comput Cardiol 41: 69-72.
41. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-106.
42. Pueyo E, Husti Z, Hornyik T, (2010). Mechanisms of ventricular rate adaptation as a predictor of arrhythmic risk. AJP-Heart Circ Physiol 298: H1577-H1587.
43. Qu Y, Ghatpande A, El-Sherif N, Boutjdir M, (2000). Gene expression of Na+/Ca2+ exchanger during development in human heart. Cardiovasc Res 45: 866-873.
44. Rodriguez B, Burrage K, Gavaghan D, Grau V, Kohl P, Noble D, (2010). The systems biology approach to drug development: application to toxicity assessment of cardiac drugs. Clin Pharmacol Ther 88: 130-134.
45. Romero L, Carbonell B, Trenor B, Rodríguez B, Saiz J, Ferrero JM, (2011). Systematic characterization of the ionic basis of rabbit cellular electrophysiology using two ventricular models. Prog Biophys Mol Biol 107: 60-73.
46. Romero L, Pueyo E, Fink M, Rodriguez B, (2009). Impact of ionic current variability on human ventricular cellular electrophysiology. AJP Heart Circ Physiol 297: H1436-H1445.
47. Romero L, Trenor B, Yang P-C, Saiz J, Clancy CE, (2014). In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome. J Mol Cell Cardiol 72: 126-137.
48. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N, (2014). Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J 167: 292-300.
49. Sartiani L, Bettiol E, Stillitano F, Mugelli A, Cerbai E, Jaconi ME, (2007). Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 25: 1136-1144.
50. Sauer AJ, Newton-Cheh C, (2012). Clinical and genetic determinants of torsade de pointes risk. Circulation 125: 1684-1694.
51. Shah RR, (2013). Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol 75: 347-358.
52. So PP-S, Backx PH, Dorian P, (2008). Slow delayed rectifier K+ current block by HMR 1556 increases dispersion of repolarization and promotes Torsades de Pointes in rabbit ventricles. Br J Pharmacol 155: 1185-1194.
53. Terrenoire C, Wang K, Tung KWC, Chung WK, Pass RH, Lu JT, et al., (2013). Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol 141: 61-72.
54. Thomas G, Gerlach U, Antzelevitch C, (2003). HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol 41: 140-147.
55. Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR, (2013). High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. Am J Physiol Heart Circ Physiol 304: H104-H117.
56. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, et al., (2011). Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471: 230-234.
57. Zemzemi N, Bernabeu MO, Saiz J, Cooper J, Pathmanathan P, Mirams GR, et al., (2013). Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials. Br J Pharmacol 168: 718-733.